Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX01 plus methotrexate in MTX-inadequate response rheumatoid arthritis (Phase III)
ChiCTR2000034167Phase 3Recruiting
- Sponsor
- Chinese Academy of Medical Sciences Peking Union Medical College
- Start
- Jun 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rituximab in rheumatoid arthritis (RA) (2 arms), sponsored by Chinese Academy of Medical Sciences Peking Union Medical College. Primary endpoint: ACR20 response at Week 24. Started Jun 2020; status: recruiting.
02
Drugs
rituximab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on ChiCTR2000034167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000034167.